December 2022 in “JAMA network open” 5α-Reductase inhibitors may increase depression risk but not dementia or suicide.
May 2024 in “European urology focus” Drugs for prostate enlargement and hair loss were not linked to increased risk of depression or suicide.
Higher doses of 5α-reductase inhibitors reduce mortality risk, while lower doses increase suicide risk.
April 2022 in “The Journal of Sexual Medicine” Finasteride alone increases suicide risk, but combining it with other treatments reduces this risk.
90 citations,
March 2017 in “JAMA Internal Medicine” Men over 66 taking medication for prostate enlargement have a higher risk of depression and self-harm, especially in the first 18 months of treatment.
1 citations,
August 2017 in “The Journal of urology/The journal of urology” 5α-reductase inhibitors may increase the risk of depression and suicidal thoughts.
May 2017 in “Psychiatric news” BPH medications may increase the risk of self-harm and depression, especially in the first 18 months.
75 citations,
January 2014 in “Korean Journal of Urology” 5α-reductase inhibitors can cause sexual problems, higher risk of aggressive prostate cancer, and depression.
January 2020 in “The Journal of Sexual Medicine” Using 5α-reductase inhibitors for hair loss can cause lasting sexual, physical, mental, and vascular health issues in men, even after stopping the medication.
35 citations,
June 2018 in “Urology” The review suggests younger men taking 1 mg finasteride report more side effects, including sexual, skin, metabolic, and psychological issues.
6 citations,
January 2020 in “Dermatology” Finasteride may increase suicide risk; more research needed.
2 citations,
March 2018 in “Current Opinion in Urology” 5-alpha reductase inhibitors can cause sexual, neurologic, endocrine, and cardiovascular side effects, but these are rare and usually stop after ending treatment.
December 2018 in “Actas urológicas españolas” 5-alpha reductase inhibitors may have additional effects on cancer, mental health, heart health, and hormone levels beyond treating prostate enlargement.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
40 citations,
June 2021 in “Clinical, cosmetic and investigational dermatology” JAK inhibitors show promise in effectively treating hair loss from alopecia areata.
1 citations,
December 2023 in “Molecules/Molecules online/Molecules annual” JAK inhibitors show promise for treating various skin diseases.
November 2024 in “Journal of Family Medicine and Primary Care” 5 alpha reductase inhibitors can cause sexual, cognitive, and muscle side effects, and may slightly increase aggressive cancer risk.
October 2022 in “Revista Eletrônica Acervo Médico” 5-Alpha-Reductase Inhibitors can cause negative side effects.
84 citations,
June 2010 in “The Plant Cell” Phospholipase A2 is necessary for the correct placement of PIN proteins in plant roots, affecting root growth.
11 citations,
August 2019 in “BMJ” Post-finasteride syndrome causes sexual, physical, and psychological symptoms, but more research is needed to understand its causes and connection to finasteride.
1 citations,
January 2014 in “Hair therapy & transplantation” Platelet-rich plasma treatment is not very effective for chronic severe alopecia areata.
7 citations,
June 2020 in “Translational Andrology and Urology” Finasteride for hair loss may cause lasting sexual, genitourinary, mental, and anti-androgenic side effects in young men.
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
54 citations,
October 2019 in “Cochrane library” Some drugs may reduce prostatitis symptoms short-term with few side effects.
1 citations,
March 2023 in “Scientific Reports” Finasteride may increase the risk of suicide or severe self-harm in men with mood disorders but not in the general population.
32 citations,
October 2004 in “Pharmacotherapy” Peginterferon alfa-2b and ribavirin therapy for hepatitis C can cause serious side effects, some different from those reported in clinical trials.
30 citations,
April 2007 in “Dermatologic Clinics” The document concludes that new treatments are needed to better manage acne and reduce side effects related to current therapies.
3 citations,
August 2011 in “Current Psychiatry Reviews” Family-based treatment is the best outpatient care for stable teens with anorexia, and more research is needed on medication and treatment effectiveness for young people with eating disorders.
June 2023 in “International journal of biology, pharmacy and allied sciences” New medications are improving depression treatment, emphasizing accurate diagnosis and chronic care.
March 2022 in “Wound practice & research” New treatments for alopecia areata show promise, but standardized guidelines are needed.